Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Current Opinion in Oncology|February 23, 2010
Molecular targeted therapies in all histologies of head and neck cancers: an updateAlbiruni R A Razak, Lillian L Siu, Christophe Le Tourneau
Plos One|December 20, 2012
Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agentsChristophe Le Tourneau, Hui K Gan, Albiruni R A Razak, et al.
Discovery Medicine|November 2, 2010
Development of anti-cancer drugsJennifer Arrondeau, Hui K Gan, Albiruni R A Razak, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2010
Nasopharyngeal carcinoma: the next challengesAlbiruni R A Razak, Lillian L Siu, Fei-Fei Liu, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2011
Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literatureChristophe Le Tourneau, Albiruni R A Razak, Hui K Gan, et al.
The British Journal of Ophthalmology|December 25, 2010
Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal glandChristophe Le Tourneau, Albiruni R A Razak, Christine Levy, et al.
The Oncologist|February 8, 2019
Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item LibraryDaniel Shepshelovich, Kate McDonald, Anna Spreafico, et al.
Cancer Treatment Reviews|February 14, 2017
Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neckRosalyn A Juergens, Scott V Bratman, Ming-Sound Tsao, et al.
The Oncologist|March 6, 2019
Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening EraTira Tan, Michael Rheaume, Lisa Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2017
Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer DrugsDiogo D G Bugano, Kenneth Hess, Denis L F Jardim, et al.
Pageof 3